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In two related papers in this issue, Bai et al. (2011a, 2011b) observe that PARP-1- or PARP-2-deficient
mice show increased energy expenditure and protection against diet-induced obesity. This metabolic
phenotype is achieved, in part, through SIRT1 activation, either by increasing NAD+ levels or by promoting
SIRT1 expression.Poly(ADP-ribose) polymerases (PARPs)
comprise a family of enzymes sharing a
conserved catalytic domain that supports
mono- or poly(ADP-ribosyl)transferase
activity using NAD+ as a donor of ADP-
ribose units. Members of the PARP family,
such as PARP-1 and PARP-2, are
involved in a wide range of molecular
and cellular processes, including mainte-
nance of genome stability, regulation of
chromatin structure and transcription,
cell proliferation, and apoptosis (Krishna-
kumar and Kraus, 2010). The focus of
the field has been on the molecular mech-
anisms underlying the role of PARPs in
these processes. Recently, however,
physiological roles of PARPs have been
moving to the forefront, as evidenced by
two articles in this issue from Bai et al.
(2011a, 2011b). In these papers, the
authors demonstrate an expanded meta-
bolic role of PARP-1 and PARP-2 upon
individual genetic depletion in mice, both
of which lead to increased energy expen-
diture and mitochondrial oxidation.
PARP-1 is the founding member of the
PARP family and contributes up to 90% of
the total cellular PARP activity. PARP-1
controls transcriptional outcomes by
modulating chromatin structure and alter-
ing the activity of chromatin- and transcrip-
tion-related factors through poly(ADP-
ribosyl)ation (PARylation) (Krishnakumar
and Kraus, 2010). To investigate the role
of PARP-1 in metabolic homeostasis, Bai
et al. (2011b) characterized the metabolic
phenotypes of PARP-1/ mice. Despite
increased food intake, the mice were
leaner, with reduced fat accumulation,
higher energy expenditure, enhanced
glucose oxidation, and protection from
diet-induced obesity as compared to theirwild-type littermates. PARP-1/ mice
also showed increased mitochondrial
content, as well as elevated oxidation-
and respiration-related gene expression in
key metabolic tissues, such asmuscle and
brown adipose tissue (BAT) (Figure 1A).
Interestingly, themetabolic phenotypes
in PARP-1/ mice resemble those in
which SIRT1, a NAD+-dependent protein
deacetylase, is overexpressed or chemi-
cally activated (Herranz and Serrano,
2010). These results suggest functional
interplay between PARP-1 and SIRT1,
perhaps since both are tightly controlled
by cellular NAD+ levels (Figure 1B).
Indeed, elevated NAD+ levels were
observed in both muscle and BAT in
PARP-1/ mice, as well as increased
SIRT1 activity, as reflected by reduced
acetylation of downstream SIRT1 targets,
including the metabolic regulators
PGC-1a and FOXO1 (Bai et al., 2011b).
The authors also recapitulated the
mitochondrial phenotypes in cell-based
assays, where PARP-1 was depleted
by RNAi or chemically inhibited by the
drug PJ34. These effects were blunted
by SIRT1 depletion, suggesting a direct
link between PARP-1 and SIRT1. The
authors posit that increased NAD+
availability might be a mechanism
by which SIRT1 is activated upon
PARP-1 knockout, depletion, or inhibition,
although other mechanisms are also
possible (Figure 1B).
The role of PARP-1 in metabolic
homeostasis, however, may not be so
simple, since other genetic determinants
could modify the phenotypic outcomes.
For example, PARP-1/ mice on
a predominantly SV129 (obesity-resistant)
background are more susceptible toCell Metabolismage-related weight gain and diet-induced
obesity than wild-type littermates (Deval-
araja-Narashimha and Padanilam, 2010;
Wang et al., 1995), while PARP-1/
mice on a predominantly C57BL/6J
(obesity-prone) background have lower
weights, exhibit improved metabolic
profiles, and are protected against diet-
induced obesity and insulin resistance
(Bai et al., 2011b; de Murcia et al., 1997).
C57BL/6J mice harbor a loss-of-function
deletion in the gene encoding nicotin-
amide nucleotide transhydrogenase, an
enzyme that catalyzes the production of
NAD+ through the reversible reduction of
NADP+ by NADH (Freeman et al., 2006).
This mutation, or perhaps a similar muta-
tion elsewhere in the genome, might
impact the phenotypes described herein.
Such possibilities should be considered
in future studies.
In a second study, Bai et al. (2011a)
used both cell- and mouse-based studies
to determine if PARP-2 plays a role in
metabolic homeostasis. PARP-2, the
closest paralog of PARP-1, shares
70% similarity with the catalytic domain
of PARP-1 and is responsible for most of
the residual PARP activity in PARP-1/
mice. In C2C12 myocytes, the authors
observed that RNAi-mediated depletion
of PARP-2 did not alter cellular NAD+
levels, but increased the levels of SIRT1
mRNA, protein, and activity. This was
reflected by reduced acetylation of
downstream SIRT1 targets, as well as
increased mitochondrial biogenesis and
oxidation. Interestingly, the authors found
that PARP-2 localizes to the SIRT1
promoter, where it functions as a negative
transcription regulator (Figure 1Bb). Thus,
PARP-2 depletion is expected to cause13, April 6, 2011 ª2011 Elsevier Inc. 353
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Figure 1. Studies withPARP-1–/– andPARP-2–/–Mice Illustrate Essential Roles for PARP-1 and PARP-2 inMetabolic Homeostasis andReveal
Several Potential Modes of Functional Interplay with SIRT1
(A) The schematic summarizes the effects of PARP-1 or PARP-2 knockout on a variety of metabolism-related phenotypes in five different tissues. The effects
(increase or decrease upon knockout) are illustrated by the use of color-coded arrows (PARP-1, red; PARP-2, blue). Many of the effects illustrated here are based
on the two papers by Bai et al., but information from other recent papers is included as well. The phenotypes shown for PARP-1 are based on PARP-1/mice
with a predominantly C57BL/6J background. Opposite effects for some parameters may be noted for PARP-1/ mice made in a predominantly SV129 back-
ground (see the text).
(B) Potential mechanisms for functional interplay and potential antagonism between PARP-1 or PARP-2 and SIRT1. The schematic illustrates four differentmodes
of functional interplay and potential antagonism between PARP-1 or PARP-2 (collectively labeled ‘‘PARP’’) and SIRT1, labeled a through d.
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Previewssimilar metabolic effects as SIRT1 activa-
tion. Indeed, the authors found that
PARP-2/ mice exhibit elevated energy
expenditure, oxygen consumption, and
lipid oxidation associated with a leaner
phenotype, as well as protection against
diet-induced obesity (Figure 1A).
The authors also observed that
PARP-2/ mice displayed a tissue-
specific mitochondrial metabolic pheno-
type, which was more evident in skeletal
muscle and liver and less so in BAT
(Bai et al., 2011a). Surprisingly, despite
an improved metabolic profile and
insulin sensitivity, PARP-2/ mice were
glucose intolerant, due to pancreatic
failure, when fed a high-fat diet. Several
key genes involved in pancreatic b cell
proliferation and function were not
induced in the PARP-2/ mice, which
can be partially explained by the
activation of FOXO1, a negative regu-
lator of pancreatic growth (Figure 1A).
The tissue-specific metabolic effects,354 Cell Metabolism 13, April 6, 2011 ª2011however, suggest that SIRT1 activation
is not the only explanation for the
observed phenotypes. Further studies
are needed to resolve this issue.
These two studies fit well with other
recent studies using knockout mouse
models to highlight the metabolic role of
PARP family members. For example, a
previous study showed that PARP-2/
mice have defects in adipogenesis
with reduced expression of adipogenic
genes (Bai et al., 2007). Tankyrase
(PARP-5) knockoutmice exhibit increased
energy expenditure, increased fatty acid
and glucose utilization, and reduced
adiposity (Yeh et al., 2009). Furthermore,
PARP-1/ mice exhibit impaired
food entrainment of peripheral circadian
clocks, supporting a role for PARP-1
in linking circadian rhythms to meta-
bolic homeostasis (Asher et al., 2010)
(Figure 1A).
Taken together, the studies summa-
rized herein raise a number of challenging,Elsevier Inc.but exciting, questions. What are
the molecular mechanisms underlying
the functional interplay of SIRT1 with
PARP-1 and PARP-2? Although potential
mechanisms have been suggested
(Figure 1B), these models need to be veri-
fied more thoroughly. In addition, what is
the molecular basis of PARP-1- and
PARP-2-dependent, SIRT1-independent
outcomes? How might cellular compart-
mentalization of NAD+ pools and
consumers (e.g., PARPs and SIRT1)
contribute? Finally, might PARP inhibitors
be useful for the treatment of metabolic
diseases? Although PARP inhibitors
have demonstrated safety and efficacy
as potential treatments for various types
of cancers (Krishnakumar and Kraus,
2010), their current lack of specificity
and potentially deleterious effects on
DNA repair pathways make their long-
term use as a treatment of metabolic
diseases a questionable, but intriguing,
possibility.
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GH, IGF-1, and insulin are emerging as important and independent mediators of tumor development and
aging. Two recent studies report that humans with GH-receptor deficiency are protected from developing
cancer through alterations in GH, IGF-1, and insulin signaling, decreasing the susceptibility of cells to DNA
damage and abnormal proliferation.The growth hormone (GH) and insulin-like
growth factor-1 (IGF-1) systems are crit-
ical for normal growth and development,
particularly during puberty, when GH
stimulates a surge in IGF-1 levels, leading
to the normal pubertal growth spurt. While
many of the functions of GH are mediated
by IGF-1, both hormones may also act
independently in various tissues. The
metabolic effects of GH generally oppose
those of insulin, whereas those of IGF-1
may support the role of insulin in metabo-
lism. As one ages, there is a gradual but
continuous reduction in circulating GH
and IGF-1 levels beginning in the third or
fourth decade of life (Parekh et al.,
2010). These reduced levels may be
partially responsible for the visceral
adiposity, sarcopenia, osteoporosis, and
other untoward changes associated with
advancing age; however, these reduc-
tions may protect against cancer devel-
opment (Parekh et al., 2010; Perrini
et al., 2010;Major et al., 2010). Two recent
studies that have attracted much atten-tion within and outside the scientific
community show that individuals with
Laron syndrome (GH receptor [GHR] defi-
ciency) have a greatly reduced, almost
absent, risk of cancer compared with indi-
viduals from the same family without the
receptor deficiency (Steuerman et al.,
2011; Guevara-Aguirre et al., 2011).
Laron syndrome is due to a mutation in
the GHR that leads to reductions in circu-
lating IGF-1 and consequent short
stature. These patients are resistant to
endogenous GH, as well as GH therapy,
due to the receptor abnormality, but clini-
cally respond quite well to rhIGF-1 injec-
tions. In the first study, Steuerman et al.
examined 230 individuals with this
disorder and found no cases of cancer,
while 8.3% of their first-degree relatives
and 22.1% of further family members
without the disorder developed various
forms of cancer (Steuerman et al., 2011).
In the second study, an Ecuadorian
cohort of individuals with the same
syndrome showed a similar result, withno cancer deaths among a population of
99 individuals and only one case of
ovarian carcinoma. In their relatives,
cancer accounted for 20% of all deaths
(Guevara-Aguirre et al., 2011). This led
both groups to postulate that the reduc-
tion in circulating levels of IGF-1 pro-
tected against cancer development.
Indeed, human mammary epithelial cells
cultured in the serumof theGHR-deficient
(GHRD) Ecuadorian cohort of patients,
were protected from oxidative DNA
damage, compared with cells cultured in
the serum of their relatives. In the setting
of oxidative stress, increased cytotoxicity
was also seen in the cells cultured in the
serum from the GHRD patients, while the
addition of IGF-1 to this serum or culturing
cells in the serum from controls reduced
the rate of cell death. In association with
these findings, the investigators reported
upregulation of proapoptotic genes, as
well as the mitochondrial superoxide dis-
mutase SOD2, and downregulation of
genes involved in cell-cycle progression,13, April 6, 2011 ª2011 Elsevier Inc. 355
